Bottom line
Infervision sells InferRead for CT lung nodules and CT stroke triage, InferOperate Suite for 3D surgical planning and InferCare for RECIST follow-up. FDA's records list six clearances, from InferRead Lung CT.AI in July 2020 (K192880) to a second InferOperate Suite entry in July 2026 (K260973). The chest X-ray product, InferRead DR Chest, has no FDA record under Infervision's applicant names. A hospital building a CT lung nodule workflow or a thoracic surgery planning service fits the cleared range. Chest X-ray AI under a US clearance is not part of what the record offers.
AI for CT lung nodules, CT stroke, surgical planning and RECIST follow-up, with FDA clearances for these CT products.
No public price.
What do the CT products do?
Infervision says InferRead CT Lung detects pulmonary nodules (pure ground glass, solid, mixed and suspected tumor), analyses lobe density and volume, registers follow-up scans with volume doubling time and produces a structured report in a browser viewer. Quantification of nodule growth, emphysema and coronary calcium is marked "For investigational use only" on the product page. The vendor claims 99% sensitivity with AI assisted reading, citing a linked publication, and a 33% cut in reading time from a talk by Wake Radiology.
Infervision says InferRead CT Stroke triages hemorrhage on head CT. FDA lists InferRead CT Stroke.AI (K211179, August 2021) as triage and notification. The Lung CT page shows FDA, NMPA and UKCA badges and no CE mark. The vendor calls the products "PACS and RIS friendly", on premise or in the cloud.
What is known about the chest X-ray product?
A 2025 PLOS Global Public Health study (PMID 40531944) by independent academic authors evaluated InferVision CAD, the InferRead DR Chest product, for tuberculosis screening in Lusaka, Zambia. At a cutoff of 0.12, sensitivity was 90.3% (86.3 to 93.5) and specificity 39.2% (36.8 to 41.7), with an AUC of 0.81. FDA has no entry for it under Infervision's applicant names.
Who is the company and what does it charge?
Infervision says it was founded in 2016, and its company page does not state a headquarters. The vendor claims deployments including Wake Radiology, Sanford Health research and TB screening in Kyrgyzstan and Zimbabwe. It publishes no price, and the site lists a contact address for enquiries.
The verdict
Thoracic surgery teams get planning software with two InferOperate Suite entries, and CT lung screening programs get nodule detection with clearances going back to July 2020. For chest X-ray AI the picture is the Zambia tuberculosis study (PMID 40531944) and no FDA record under Infervision's applicant names.
Editorial review last generated November 2, 2026. Synthesized from clinician sentiment, peer-reviewed coverage, and our editorial silo picks. Refined by hand where vendor facts change.






